Skip Nav Destination
Issues
1 December 2024
-
Cover Image
Cover Image
The cover image is adapted from Fig. 1 in the article, “Cancer Mortality among Hispanic Groups in the United States, by Birthplace (2003–2017),” by He and colleagues. This study examined cancer mortality burden by sex, birthplace, and cancer sites in disaggregated Hispanic American groups from 2003 to 2017 and aimed to describe and compare patterns over time. The authors estimated, directly and indirectly, age adjusted 5-year mortality rates and modeled mortality trends, by joint Hispanic ethnicity and nativity, focusing on cancer sites that were potentially affected by predominant risk factors. A total of 228,197 Hispanic decedents [Mexican, Puerto Rican (PR), Cuban, and Central or South American] with cancer-related deaths from US death certificates (2003–2017) were analyzed. Figure 1 shows trends by selected cancer sites among males (2003–2017). Puerto Rico-born PRs, Cuba-born Cubans, and USborn Mexicans had some of the highest cancer death rates among all the Hispanic groups. In general, foreign-born Hispanics had higher cancer mortality rates than US-born, except Mexicans. Overall, US-born and non-US-born (i.e., native- or foreign- born) Hispanic groups experienced decreasing rates of cancer deaths over the years. The authors noted vast heterogeneity in mortality rates by nativity across Hispanic groups, a fast-growing diverse US population. Understanding disaggregated patterns and trends in cancer burden can motivate deeper discussion around community health resources, which may improve the health of Hispanics across the United States. For more information, see the article beginning on page 1598. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1055-9965
EISSN 1538-7755
Highlights
In the Spotlight
Commentaries
Resource Report
The University of North Carolina Cancer Survivorship Cohort: A Resource for Collaborative Survivorship Research
Chelsea Anderson; Jeannette T. Bensen; Emma H. Allott; Patricia V. Basta; Debra E. Irwin; Adrian Gerstel; Laura Farnan; Hung-Jui Tan; Erin E. Kent; Tzy-Mey Kuo; Christopher D. Baggett; Andrew F. Olshan; H. Shelton Earp; Hazel B. Nichols
Research Articles
High Incidence of Gastric Cancer in El Salvador: A National Multisectorial Study during 2000 to 2014
Lisseth Ruiz de Campos; Marisabel Valdez de Cuellar; Dalton A. Norwood; Tiffany Y. Carrasco; Eleazar E. Montalvan-Sanchez; Maria-Virginia Rodriguez Funes; Timothy Beasley; Ricardo L. Dominguez; Luis E. Bravo; Douglas R. Morgan
Associations of Prostate Tumor Immune Landscape with Vigorous Physical Activity and Prostate Cancer Progression
Lanshan Huang; Sarah J. Winter; Linnea T. Olsson; Alina M. Hamilton; Sophia R. Halliday; Erin L. Kirk; Laura Farnan; Adrian Gerstel; Stephanie G. Craig; Stephen P. Finn; Melissa LaBonte Wilson; Suneil Jain; Melissa A. Troester; Eboneé N. Butler; Jeannette T. Bensen; Sara E. Wobker; Emma H. Allott
Adiposity throughout Adulthood and Risk of Young-Onset Breast Cancer Tumor Subtypes in the Young Women’s Health History Study
Lydia Marcus Post; Dorothy R. Pathak; Ann S. Hamilton; Kelly A. Hirko; Richard T. Houang; Emily H. Guseman; Dan Sanfelippo; Nicole Bohme Carnegie; L. Karl Olson; Hallgeir Rui; Ann G. Schwartz; Ellen M. Velie
Excess Mortality in Persons with Concurrent HIV and Cancer Diagnoses: A Retrospective Cohort Study
Kamaria L. Lee; Varada Sarovar; Jennifer O. Lam; Wendy A. Leyden; Stacey E. Alexeeff; Alexandra N. Lea; Rulin C. Hechter; Haihong Hu; Julia L. Marcus; Qing Yuan; Jennifer R. Kramer; Lilie L. Lin; Elizabeth Y. Chiao; William J. Towner; Michael A. Horberg; Michael J. Silverberg
Null Results in Brief
Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis
Emma Hazelwood; Catalina Lopez Manzano; Emma E. Vincent; Demetrius Albanes; David Timothy Bishop; Loïc Le Marchand; Cornelia M. Ulrich; Ulrike Peters; Gwen Murphy; Niloy Jewel Samadder; Laura Anderson; Marc J. Gunter; Neil Murphy; Bethany Van Guelpen; Nikos Papadimitriou
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.